Difference between revisions of "Copanlisib (Aliqopa)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed [[follicular lymphoma]] who have received at least two prior systemic therapies." | *9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed [[follicular lymphoma]] who have received at least two prior systemic therapies." | ||
| + | |||
| + | ==Patient Information== | ||
| + | *[http://labeling.bayerhealthcare.com/html/products/pi/Aliqopa_PI.pdf Copanlisib (Aliqopa) package insert]<ref name="insert"></ref> | ||
==Also known as== | ==Also known as== | ||
Revision as of 10:35, 4 April 2021
General information
Class/mechanism: From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies."
Patient Information
Also known as
- Code name: BAY 80-6946
- Brand name: Aliqopa